



*Fernão Vaz Dourado, 1571*

Healthy People 2020



196	recommended care
198	ACEI/ARB treatment
199	incidence of ESRD
200	kidney failure due to diabetes
202	nephrologist care
203	vascular access
206	transplantation
209	mortality
214	summary

The Healthy People program, now in its third decade, was established to improve the health of all Americans through the development and evaluation of national health objectives. HP2020, launched on December 2, 2010, is the next step in the continuum of care, with its foundation based on the success of the four previous HP initiatives.

One of the major goals of the HP2020 program is to “reduce new cases of chronic kidney disease (CKD) and its complications, disability, death, and economic costs.” The development and progression of CKD, which results in reduced quality of life, is a major health concern. The HP2020 CKD objectives are designed to further reduce the long-term burden of kidney disease, improve the quality of life among those with the condition, and eliminate disparities — racial or otherwise — within the healthcare system. To accomplish these goals, the HP2020 program developed 14 objectives related to CKD, along with targets designed to evaluate the program’s success. We provide data for ten of these objectives, plus information on urine albumin testing in non-CKD patients diagnosed with diabetes. Because we use the Medicare 5 percent data to evaluate objectives related to CKD patients not on dialysis, results are limited to those age 65 and older.

In 2011, 13.1 percent of hospital patients with acute kidney injury had a follow-up renal evaluation six months post-discharge, a slight increase from the 11.8 percent seen in 2010, yet above the objective’s modest goal of 12.4 percent.

Patients with diabetes are at increased risk of CKD. HP2020 has set a goal that 37 percent of persons with diagnosed diabetes obtain an annual urine albumin measurement. The percentage of elderly patients with diabetes receiving this measurement rose from 15.4 in 2001 to 40.8 in 2011, just over the suggested HP2020 target, but less than would be expected from clinical guidelines.

Serum creatinine and urine albumin are important laboratory markers for monitoring the presence and progression of CKD, and lipid tests are important for assessing cardiovascular risk in this population. In 2011, 30.3 percent of patients received these recommended medical evaluations, an increase from 29.0 percent in 2010, and slightly above the recommended HP2020 target of 28.4 percent.

Patients with either Type 1 or Type 2 diabetes and CKD require more comprehensive laboratory monitoring. The hemoglobin A1c test is used to assess blood glucose control over prolonged periods of time in patients with diabetes, while diabetic retinopathy can be detected through regular eye examinations. Twenty-seven percent of elderly diabetic patients receive A1c and eye testing along with serum creatinine, lipid, and urine albumin tests,



*We need the tonic of wildness... At the same time that we are earnest to explore and learn all things, we require that all things be mysterious and unexplorable, that land and sea be indefinitely wild, unsurveyed and unfathomed by us because unfathomable. We can never have enough of nature.*

*Henry David Thoreau*  
WALDEN: OR, LIFE IN THE WOODS

almost meeting the HP2020 target of 25.4 percent, but a level certainly in need of further improvement.

Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) is a recommended medical treatment to slow the progression of CKD in patients with diabetes and CKD. Among 2011 fee-for-service beneficiaries age 65 and older, enrolled in Part D, and with diabetes and CKD, 72 percent received these medications, well above the now outdated HP2020 target of 60 percent.

A major HP2020 health objective is targeted at reducing new cases of ESRD, a disease which greatly affects an individual's quality of life, and is an enormous burden on the healthcare system, accounting for approximately 6.3 percent (\$34 billion) of total Medicare costs in 2011. In 2011, the rate of new ESRD cases was 357 per million population, 12 percent above the new HP2020 target of 318.5, and down from 375 in 2001.

Patients with diabetes are at increased risk of ESRD. The rate of kidney failure due to diabetes fell to 155.7 per million population in 2011, yet remains 11.9 percent above the HP2020 target of 139.2.

In past ADRS the USRDS raised concerns that late referral to a nephrologist prior to ESRD, or the lack of such referral, may contribute to higher morbidity and mortality in the first year of treatment. HP2020 has set a target referral rate of 29.8 percent — a conservative goal that should be updated. Rates have increased since 2005, from 25.6 percent to 30.8 percent in 2011, and now exceed the target.

We have reported on the high use of catheters at the first outpatient hemodialysis session, and on the associated risks. Among patients who have seen a nephrologist for more than a year, fewer than half use a catheter during their first outpatient dialysis session; they also have the greatest likelihood at initiation of having an arteriovenous (AV) fistula or maturing internal access. In an effort to improve vascular access for hemodialysis patients, HP2020 has developed objectives designed to increase the use of AV fistulas. In 2007, 49.6 percent

of prevalent hemodialysis patients had an AV fistula as their primary vascular access, just under the 50.6 percent HP2020 target. The proportion of prevalent patients using a catheter as the only mode of vascular access stood at 27.7 percent in 2007, slightly above the target of 26.1 percent. And in 2011, 34.8 percent of incident hemodialysis patients used an AV fistula or had a maturing fistula as their primary mode of vascular access, exceeding the HP2020 target of 34.5 percent.

ESRD patients who receive a kidney transplant have lower mortality and hospitalization rates than those on dialysis. First-year all-cause mortality rates in hemodialysis patients, for example, are nearly five times higher than rates among transplant patients. HP2020 has set a goal of 18.8 percent of dialysis patients younger than 70 being wait-listed and/or receiving a deceased donor kidney transplant within one year of ESRD initiation. In 2010, 16.9 percent of patients met this criterion. Additional goals call for 19.7 percent of patients with treated chronic kidney failure to receive a transplant with three years of registration on the waiting list (the number was 16.2 for 2007 patients but fell to 15.2 in 2008), and for increasing the number who receive a transplant at the start of ESRD; of 2011 incident patients younger than 70, only 3.3 percent received a preemptive transplant.

Expanded HP2020 objectives call for reductions in total death rates for persons on dialysis, reduced death rates in the first three months of renal replacement therapy, and a reduced cardiovascular death rate in dialysis and transplant patients. The most impressive gain toward achieving an HP2020 objective is the continued decline in cardiovascular mortality rates in prevalent dialysis patients, from 118.6 deaths per 1,000 patient years at risk in 2001 to 76.6 in 2011, below the HP2020 goal of 81.3. There have also been positive developments in reducing the death rate in dialysis patients in the first three months after initiation of therapy, from 384.2 in 2001 to 335.4 in 2011; this remains far, however, from the target of 319.9.

Additional information on the HP2020 program objectives can be found at [www.healthypeople.gov](http://www.healthypeople.gov).

*Each year's USRDS Annual Data Report includes re-estimates of earlier year rates due to some lag in reporting new cases of ESRD. Therefore, the original Healthy People 2020 baselines were revised and the targets were proportionally adjusted using the original target-setting method.*



### HP2020 CKD-3

Increase the proportion of hospital patients who incurred acute kidney injury who have follow-up renal evaluation in six months post discharge

**TARGET: 12.4%**

In 2001, just 2.5 percent of patients age 65 and older who were hospitalized for acute kidney injury had a follow-up renal evaluation during the following six months. By 2011 this had increased to 13.1 percent, for the first time meeting the Healthy People 2020 goal of 12.4 percent.

The lowest rate of follow-up evaluation occurs in the oldest patients, with

just 6.3 percent of those age 85 and older receiving such care, compared to 18.2 percent of those age 65–74. By race and ethnicity, rates range from 12.9 percent of whites to 17.4 percent among Asians. + **Table HP2020 CKD-3**; see page 428 for analytical methods. *Medicare patients age 65 & older (5 percent Medicare sample) with a hospitalized AKI event in given year.*

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	2.5	3.3	4.5	8.4	9.0	10.4	11.1	10.4	11.3	11.8	13.1
American Indian or Alaskan Native only	0.0	0.0	3.3	14.3	5.2	11.3	11.1	12.9	6.7	11.5	14.6
Asian only	3.2	2.4	4.0	7.3	12.3	20.8	14.4	11.7	17.4	15.3	17.4
Black or African American only	3.1	2.6	4.2	8.1	9.9	9.3	10.9	10.2	12.1	11.2	13.3
White only	2.4	3.3	4.5	8.4	8.7	10.4	11.1	10.2	11.0	11.7	12.9
Hispanic or Latino	1.6	7.3	7.7	13.2	13.0	10.2	11.3	14.6	12.6	13.0	16.5
Male	2.9	3.7	4.7	8.9	9.9	11.3	12.4	11.6	12.3	12.7	14.4
Female	2.2	2.9	4.4	8.0	8.2	9.6	9.9	9.3	10.4	11.0	12.0
65-74	4.0	4.4	6.4	11.8	12.9	14.8	15.9	14.4	15.7	16.3	18.2
75-84	2.1	3.4	4.4	8.6	8.6	10.4	11.2	10.7	11.2	12.3	13.8
85+	0.7	1.2	2.1	3.1	4.4	5.0	5.01	4.97	6.33	5.84	6.3

### HP2020 D-I2

Increase the proportion of persons with diagnosed diabetes who obtain an annual urine albumin measurement

**TARGET: 37.0%**

In the diabetic population age 65 and older, the percentage of patients receiving an annual urine albumin measurement has increased from 15.4 in 2001 to 40.8 in 2011, exceeding the HP2020 target of 37 percent.

Rates fall with age, from 45 percent in patients age 65–74 to 27 percent of those 85 and older. By race and ethnicity, rates range from 25 percent among American Indians/Alaskan Natives

to 44 percent in the Asian population. Testing may, however, be under-reported in Native Americans, as the Indian Health Service does not report claims through the Medicare system.

Rates vary little by gender, at 42 percent for men and 40 percent for women in 2011. + **Table HP2020 D-I2**; see page 429 for analytical methods. *Medicare patients with diabetes, age 65 & older.*

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	15.4	18.4	21.4	25.8	28.7	31.3	33.6	35.6	37.3	38.8	40.8
American Indian or Alaskan Native only	11.6	12.2	13.1	15.6	19.5	19.8	21.1	21.1	24.0	23.3	24.7
Asian only	16.9	20.9	24.1	29.0	30.8	33.8	35.2	37.5	39.9	42.1	43.9
Black or African American only	13.3	15.8	18.9	23.8	26.7	29.5	31.9	33.7	35.7	37.1	39.3
White only	15.7	18.7	21.8	26.0	28.9	31.4	33.8	35.8	37.4	38.9	40.8
Hispanic or Latino	15.4	18.0	20.7	25.9	29.8	31.4	33.6	35.6	38.1	40.4	42.6
Male	16.1	19.1	22.1	26.7	29.6	32.2	34.6	36.6	38.2	39.8	41.8
Female	15.0	17.9	20.9	25.1	28.1	30.6	32.7	34.8	36.6	38.0	39.9
65-74	18.2	21.4	24.8	29.5	32.6	35.2	37.7	40.0	41.9	43.3	45.3
75-84	13.7	16.7	19.6	23.8	26.8	29.6	31.8	33.7	35.3	37.1	39.2
85+	7.2	9.0	10.9	13.8	16.1	18.1	20.5	22.2	23.5	25.0	26.7



## HP2020 CKD-4

Increase the proportion of persons with diabetes and chronic kidney disease who receive recommended medical evaluations

In the Medicare CKD population age 65 and older, 30 percent of patients received serum creatinine, lipid, and urine albumin testing in 2011 — a considerable increase from the level of 7.3 percent in 2001, and exceeding the Healthy People 2020 goal of 28.4 percent. Testing rates by race range from 21 percent among American Indians/Alaskan Natives to 40 percent among Asians. Rates by gender are 29 percent in women compared to 32 percent in men, and by age are lowest among the oldest patients, at 16 percent.

In the diabetic CKD population age 65 and older, 27 percent of patients in 2011 received serum creatinine, urine

albumin, glycosylated hemoglobin (A1c), and lipid testing, as well as an eye examination; this also meets the HP2020 goal, set at 25.4 percent. The reported percentage of patients receiving comprehensive diabetic testing is lowest among American Indians/Alaskan Natives, at 14 percent (care provided by the Indian Health Service, however, is not reported to Medicare), and highest among Asians, at 31 percent. Rates vary little by gender, and decrease with age. + **Tables HP2020 CKD-4**; see page 429 for analytical methods. *Medicare patients age 65 & older with CKD (4.1–2) & diabetes (4.2).*

### HP2020 CKD-4.1 TARGET: 28.4%

Increase the proportion of persons with chronic kidney disease who receive medical evaluation with serum creatinine, lipids, and urine albumin

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	7.3	9.1	10.6	19.8	22.1	23.4	25.7	26.7	28.1	29.0	30.3
American Indian or Alaskan Native only	8.2	5.5	7.0	13.7	19.2	15.9	16.9	16.8	18.4	20.4	21.2
Asian only	8.4	14.4	14.2	27.5	28.1	32.6	35.3	34.1	37.7	36.9	39.6
Black or African American only	6.6	8.7	10.0	20.8	22.8	24.4	26.7	27.9	30.1	30.7	32.4
White only	7.1	8.8	10.4	19.3	21.6	22.9	25.1	26.3	27.4	28.3	29.5
Hispanic or Latino	13.1	17.3	17.7	26.8	30.5	31.1	33.1	32.1	36.0	36.8	39.1
Male	7.5	9.3	11.3	21.1	23.4	24.5	27.1	28.4	29.6	30.6	32.1
Female	7.0	8.9	10.0	18.6	20.9	22.4	24.4	25.2	26.7	27.6	28.7
65-74	10.3	12.6	14.2	26.1	29.2	31.4	33.9	35.1	36.7	37.7	39.0
75-84	6.2	8.0	9.8	18.5	20.8	22.6	24.9	26.2	27.7	28.9	30.3
85+	2.3	3.1	4.0	8.2	10.0	10.1	12.1	13.1	14.0	14.8	16.3

### HP2020 CKD-4.2 TARGET: 25.4%

Increase the proportion of persons with type 1 or type 2 diabetes and chronic kidney disease who receive medical evaluation with serum creatinine, urine albumin, HbA1c, lipids, and eye examinations

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	9.0	10.4	12.1	18.4	20.0	21.1	23.0	23.7	25.1	26.5	27.0
American Indian or Alaskan Native only	7.3	2.4	5.7	5.6	15.8	12.6	10.2	10.9	11.0	15.2	14.3
Asian only	8.3	12.4	12.8	25.2	21.9	26.3	26.7	25.2	27.0	29.5	30.8
Black or African American only	6.7	7.2	9.9	16.3	17.9	18.8	19.8	21.2	22.4	23.8	25.2
White only	9.4	11.0	12.5	18.6	20.3	21.4	23.4	24.1	25.6	27.0	27.2
Hispanic or Latino	10.4	11.8	11.8	20.4	20.4	19.8	22.2	21.8	24.6	24.1	26.6
Male	9.3	10.6	12.4	18.8	20.3	21.4	23.5	23.7	25.6	26.7	27.4
Female	8.7	10.3	11.8	18.0	19.7	20.9	22.5	23.6	24.7	26.3	26.7
65-74	10.9	12.3	14.3	22.0	23.4	24.6	26.6	27.2	28.5	30.1	30.2
75-84	8.1	9.9	11.7	16.9	18.9	20.7	22.6	23.3	25.2	26.7	27.5
85+	4.0	4.2	4.9	9.5	11.6	11.3	13.0	14.2	15.5	16.6	17.8



## HP2020 CKD-5

Increase the proportion of persons with diabetes and chronic kidney disease who receive recommended medical treatment with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

**TARGET: 81.0%**

In 2011, 72 percent of patients age 65 and older with diabetes and CKD received recommended medical treatment with angiotensin-converting enzyme inhibitors (ACEIS) or angiotensin II receptor blockers (ARBs), considerably higher than the revised Healthy People 2020 target of 81 percent.

By race, the percentage of patients receiving this treatment ranges from 70

among whites to 80 among Asians. Use varies little by gender, at 70–73 percent. And by age, 75, 71, and 63 percent, respectively, of patients age 65–74, 75–84, and 85 and older received ACEIS/ARBs in 2011. + **Table HP2020 CKD-5**; see page 429 for analytical methods. *Fee-for-service beneficiaries enrolled in Medicare Part D, age 65 & older.*

	2006	2007	2008	2009	2010	2011
All	71.8	73.6	73.5	73.3	72.6	71.7
American Indian or Alaskan Native only	65.4	71.0	78.5	75.3	73.3	74.9
Asian only	77.4	79.7	80.5	79.9	81.0	79.5
Black or African American only	75.6	77.0	74.8	76.2	74.9	75.1
White only	70.2	72.3	72.5	72.1	71.1	70.2
Hispanic or Latino	78.5	77.3	77.4	77.6	79.4	78.7
Male	68.3	70.5	71.2	71.1	70.6	69.8
Female	74.1	75.7	75.1	74.9	73.9	73.1
65-74	75.7	77.6	77.5	77.2	76.5	75.4
75-84	70.3	72.4	72.3	71.9	71.1	71.2
85+	64.4	65.3	65.3	66.2	65.5	63.3





## HP2020 CKD-8

Reduce the rate of new cases of end-stage renal disease (ESRD)

**TARGET: 318.5 NEW CASES PER MILLION POPULATION**

At 357 per million population, the rate of new cases of ESRD is now 5 percent greater than in 2001, and remains considerably higher than the HP2020 goal of 318.5.

There is substantial variation by race in the rate of new ESRD cases. Among whites and Asians, for example, the rates are 286 and 347, respectively. But the rate among blacks/African Americans is 971, and for Native Hawaiians/Pacific Islanders it reaches 2,368. By ethnicity, the rate ranges from 346 among those who are not

Hispanic or Latino to 537 among those who are. And the rate of 450 cases per million population among men is 60 percent greater than the rate of 282 among women. + **Table HP2020 CKD-8**; see page 429 for analytical methods. *Incident ESRD patients. Adj: overall, age/gender/race; rates by age adjusted for gender/race; rates by gender adjusted for age/race; rates by race/ethnicity adjusted for age/gender. Ref: 2010 patients. "." Zero values in this cell. \*Values for cells with ten or fewer patients are suppressed.*

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	375.3	375.9	377.5	379.2	382.4	390.0	382.6	378.6	381.5	373.9	356.7
American Indian or Alaskan Native only	691.1	655.7	604.3	617.7	598.4	512.8	527.8	540.4	526.7	484.9	457.0
Asian only	310.6	303.8	297.4	279.8	333.2	353.1	354.1	352.9	360.2	354.2	346.8
Native Hawaiian or other Pac. Islander only	3,324.0	3,424.3	3,459.9	3,622.6	2,863.3	2,817.2	2,362.8	2,146.2	2,408.1	2,594.4	2,368.0
Black or African American only	1,097.1	1,104.8	1,105.5	1,072.6	1,082.8	1,092.1	1,070.2	1,053.0	1,052.2	1,014.5	970.5
White only	283.6	284.5	286.2	292.5	296.2	306.8	301.6	299.4	303.1	299.7	286.1
2 or more races	.	*	*	*	111.1	128.5	131.3	126.7	109.4	102.1	71.8
Hispanic or Latino	600.2	610.6	617.4	605.0	589.0	592.2	574.9	569.9	562.5	554.2	536.6
Not Hispanic or Latino	362.4	362.5	364.6	367.5	369.7	375.3	369.0	365.8	370.0	362.9	346.3
Black or Af Am only, not Hispanic/Latino	1,117.8	1,125.6	1,128.0	1,092.5	1,104.3	1,114.8	1,095.6	1,078.6	1,078.6	1,041.2	996.4
White only, not Hispanic or Latino	262.3	261.2	262.0	268.6	270.3	276.3	270.8	267.8	271.2	267.0	252.7
Male	450.2	455.9	456.9	466.8	473.0	484.1	476.9	474.1	478.9	471.2	449.8
Female	316.0	312.9	315.2	309.9	310.9	315.3	308.3	303.1	304.4	296.5	281.8
<18	11.6	11.9	12.1	12.8	12.7	11.9	12.6	12.7	13.0	13.1	13.1
0-4	9.4	8.0	9.4	11.1	10.3	9.3	11.3	10.6	13.6	15.0	15.0
5-11	7.4	8.9	7.6	7.9	8.0	6.8	7.1	7.8	7.3	7.4	7.1
12-17	18.2	18.7	19.8	20.1	20.3	19.8	20.2	20.2	19.2	18.1	18.5
18-44	112.4	111.7	111.6	114.0	119.3	123.4	122.0	121.6	125.5	121.5	117.9
18-24	43.9	41.9	42.7	41.3	44.5	45.2	44.8	43.6	42.8	41.6	41.5
25-44	136.3	136.1	135.7	139.4	145.4	150.7	149.0	149.0	154.4	149.5	144.6
45-64	612.3	602.0	606.4	603.7	604.9	615.5	601.2	595.7	594.8	578.4	555.3
45-54	388.0	386.2	389.7	390.3	388.2	406.6	394.0	389.4	391.2	376.6	373.6
55-64	836.7	817.8	823.0	817.0	821.5	824.3	808.4	802.1	798.3	780.3	737.1
65+	1,574.1	1,617.6	1,611.2	1,615.0	1,634.9	1,655.4	1,622.9	1,599.0	1,609.2	1,598.6	1,510.2
65-74	1,431.4	1,418.3	1,403.8	1,404.1	1,390.2	1,418.1	1,383.9	1,354.2	1,360.3	1,351.2	1,263.1
75-84	1,748.2	1,844.2	1,838.8	1,844.3	1,895.4	1,910.0	1,873.0	1,850.8	1,863.4	1,856.5	1,771.0
85+	1,259.1	1,344.2	1,408.7	1,430.3	1,475.6	1,482.2	1,511.2	1,527.9	1,556.2	1,493.4	1,372.6



## HP2020 CKD-9

Reduce kidney failure due to diabetes

The rate of kidney failure due to diabetes has decreased 9 percent in the last decade, reaching 156 per million population in 2011. The HP2020 goal of 139.2 is met only by whites, patients of two or more races, women, and patients age 44 and younger. The highest rate of diabetic ESRD occurs among Native Hawaiians/Pacific Islanders, at 1,439; the rate among blacks/African Americans reaches 424.

In 2011, the adjusted rate of kidney failure due to diabetes among diabetic patients was 2,296 per million population, 13.2 percent lower than in 2007, and below the HP2020

target of 2,374. Rates have fallen 13.5 and 14.8 percent, respectively, among whites and blacks/African Americans, and 14.6 percent in those of Hispanic or Latino ethnicity. By gender, rates have decreased 14.0 and 13.1 percent in males and females, to 2,543 and 2,045 per million. ♦ **Tables HP2020 CKD-9; see page 429 for analytical methods. Incident ESRD patients. Adj: age/gender/race; ref: 2010. NHIS 2006–2011 used to estimate diabetes prevalence; SUDAN used for national estimates (9.2). “.” Zero values in this cell. \*Values for cells with ten or fewer patients are suppressed.**

### HP2020 CKD-9.1 TARGET: 139.2 PER MILLION POPULATION

Reduce kidney failure due to diabetes

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	171.4	168.7	168.7	169.2	169.1	172.9	167.3	164.9	165.8	163.1	155.7
American Indian or Alaskan Native only	512.2	480.3	455.9	462.9	418.6	356.3	369.7	387.7	381.0	345.5	320.3
Asian only	147.0	137.6	135.7	126.5	156.2	175.6	171.1	178.1	177.1	170.9	173.0
Native Hawaiian or other Pacific Islander only	2,106.0	1,911.8	1,943.8	2,191.8	1,651.9	1,703.0	1,464.4	1,286.6	1,517.1	1,630.2	1,438.8
Black or African American only	510.2	504.1	497.0	483.3	485.4	489.8	467.9	462.8	461.5	447.2	424.4
White only	129.1	127.8	128.7	131.3	131.9	137.1	133.9	131.8	133.1	132.4	126.9
2 or more races	.	*	*	*	55.2	67.2	69.2	59.8	58.7	46.6	34.3
Hispanic or Latino	384.8	387.4	392.3	385.3	366.4	367.1	356.7	356.5	346.3	343.4	328.9
Not Hispanic or Latino	160.1	157.2	157.3	158.4	158.2	160.9	155.8	153.6	155.3	152.7	146.0
Black or Af Am only, not Hispanic/Latino	519.1	512.4	505.4	491.1	493.9	498.2	477.5	472.5	472.0	457.2	434.6
White only, not Hispanic or Latino	111.7	109.5	109.5	111.9	111.8	114.4	110.8	107.6	109.0	107.6	102.0
Male	187.8	188.3	189.2	194.9	196.1	201.7	197.4	195.9	198.6	196.3	188.5
Female	157.5	152.2	151.7	147.8	146.7	148.8	142.4	139.2	138.6	135.4	128.2
<18	0.1	0.1	*	0.1	0.1	0.1	0.1	0.1	0.4	0.5	0.6
0-4	*	*	*	*	0.3	*	0.1	0.2	1.2	1.5	1.6
5-11	*	0.2	.	.	.	.	.	*	.	*	*
12-17	*	*	*	*	0.2	0.2	*	0.2	0.2	0.3	0.3
18-44	33.8	32.8	33.7	34.8	35.7	39.0	38.5	38.6	40.9	40.5	40.6
18-24	3.6	3.0	3.0	2.2	3.3	3.3	2.8	2.6	2.8	2.6	2.6
25-44	44.3	43.2	44.5	46.2	47.0	51.5	51.0	51.1	54.3	53.8	53.9
45-64	342.8	332.2	329.5	325.9	325.5	326.3	312.9	310.5	308.8	298.0	282.2
45-54	191.1	188.2	187.4	186.7	184.0	191.7	181.5	180.6	182.3	178.2	175.3
55-64	494.4	476.2	471.7	465.1	466.9	460.9	444.3	440.4	435.4	417.7	389.1
65+	675.3	685.7	681.9	691.6	695.0	708.0	692.4	674.6	675.7	679.1	644.3
65-74	745.9	731.0	727.4	724.9	715.1	728.8	701.9	680.3	677.9	669.3	630.3
75-84	644.6	678.8	672.7	693.2	711.4	722.0	715.5	698.2	701.7	717.7	686.4
85+	275.6	300.6	318.3	342.9	330.7	360.6	367.6	381.6	394.2	391.6	362.7



pr  
hp

1

2

3

4

5

6

7

8

9

10

11

12

201

**HP2020 CKD-9.2 TARGET: 2,374.I PER MILLION POPULATION**  
 Reduce kidney failure due to diabetes among persons with diabetes

	2007	2008	2009	2010	2011
All	2,645	2,514	2,431	2,375	2,296
American Indian or Alaskan Native only	2,582	2,982	2,975	2,649	2,294
Asian only	2,115	2,234	2,245	2,172	2,160
Native Hawaiian or other Pacific Islander only	.	.	.	.	.
Black or African American only	4,508	4,361	4,277	4,013	3,840
White only	2,307	2,169	2,080	2,058	1,995
2 or more races	537	432	397	325	294
Hispanic or Latino	3,346	3,194	2,956	2,905	2,857
Not Hispanic or Latino	2,544	2,418	2,352	2,294	2,210
Black or Af Am only, not Hispanic/Latino	4,733	4,568	4,524	4,240	4,099
White only, not Hispanic or Latino	2,071	1,926	1,853	1,829	1,756
Male	2,957	2,769	2,651	2,571	2,543
Female	2,354	2,266	2,208	2,172	2,045
<18	29	73	183	240	270
0-4	.	.	.	.	.
5-11	*	.	.	.	.
12-17	16	57	57	94	76
18-44	1,643	1,575	1,545	1,497	1,596
18-24	351	294	304	309	381
25-44	1,781	1,724	1,683	1,616	1,703
45-64	2,408	2,282	2,222	2,167	2,092
45-54	2,039	1,874	1,885	1,902	1,908
55-64	2,671	2,594	2,459	2,338	2,197
65+	3,123	2,962	2,827	2,742	2,587
65-74	3,216	3,016	2,923	2,789	2,635
75-84	3,364	3,172	2,957	2,892	2,807
85+	1,964	2,103	2,006	2,132	1,791

LA MERIQUE  
 dirigee  
 PAR GRANDS ETATS  
 Par le Dr. J. B. SARTRE  
 A PARIS



## HP2020 CKD-IO

Increase the proportion of chronic kidney disease patients receiving care from a nephrologist at least 12 months before the start of renal replacement therapy

**TARGET: 29.8%**

In 2011, 31 percent of patients beginning ESRD therapy on hemodialysis had seen a nephrologist for at least 12 months prior to initiation, fulfilling the goal of 29.8 percent set by Healthy People 2020, and up from the level of 26 percent seen in 2005.

By race, rates of pre-ESRD nephrologist care range from 27 percent among Native Hawaiians/ Pacific Islanders to 33 percent among whites; rates by ethnicity are lowest among

Hispanics/Latinos, at 24 percent. There is little difference in pre-ESRD care by gender; by age, however, rates range from 25 percent among those age 18–44 to 43 percent in the pediatric population. † **Table HP2020 CKD-IO**; see page 429 for analytical methods. *Incident hemodialysis patients with a valid Medical Evidence form; nephrologist care determined from Medical Evidence form.*

	2005	2006	2007	2008	2009	2010	2011
All	25.6	26.3	27.1	28.4	28.4	29.4	30.8
American Indian or Alaskan Native only	25.3	27.1	25.8	27.7	27.0	24.2	28.0
Asian only	25.6	23.9	26.2	27.5	29.0	29.6	31.4
Native Hawaiian or other Pacific Islander only	23.0	24.8	23.6	22.1	23.5	24.7	26.7
Black or African American only	22.1	23.1	24.0	24.6	24.9	25.5	27.1
White only	27.1	27.8	28.6	30.1	29.9	31.1	32.5
2 or more races	22.1	21.9	23.8	28.3	26.0	28.7	27.9
Hispanic or Latino	19.2	20.6	20.5	21.5	21.7	22.8	24.0
Not Hispanic or Latino	26.5	27.2	28.2	29.5	29.4	30.4	32.0
Black or Af Am only, not Hispanic/Latino	22.1	23.1	24.1	24.6	24.9	25.5	27.2
White only, not Hispanic or Latino	28.7	29.4	30.4	32.1	31.9	33.1	34.7
Male	26.0	26.4	27.2	28.2	28.1	29.4	30.6
Female	25.1	26.2	27.1	28.6	28.7	29.3	31.2
<18	39.4	34.3	33.5	37.7	37.6	36.7	42.9
0-4	26.6	17.3	25.1	25.3	24.5	25.2	26.7
5-11	48.6	47.0	39.0	49.5	46.7	48.6	57.8
12-17	41.9	36.1	35.2	38.2	40.2	37.2	44.7
18-44	22.9	22.6	23.1	23.9	23.4	23.8	25.1
18-24	23.3	22.7	23.1	23.1	22.9	24.2	26.4
25-44	22.9	22.6	23.1	24.0	23.4	23.7	24.9
45-64	25.5	26.0	26.5	27.1	27.2	27.7	29.3
45-54	24.0	24.9	25.4	25.2	25.5	26.0	28.2
55-64	26.5	26.7	27.3	28.5	28.3	28.8	30.0
65+	26.0	27.4	28.6	30.3	30.4	31.9	33.4
65-74	27.0	28.3	28.7	30.4	30.6	32.0	33.4
75-84	25.7	27.3	28.9	31.1	30.9	32.6	33.9
85+	22.8	24.1	26.8	27.4	28.3	29.4	31.5





## HP2020 CKD-II

Improve vascular access  
for hemodialysis patients

Identified through the ESRD CPM data-set, use of an arteriovenous (AV) fistula as the primary mode of vascular access in prevalent hemodialysis patients increased from 27 percent in 1998 to 50 percent in 2007 (the most recent year of available CPM data). By race, use is highest among Asian patients, at 57 percent, and lowest among African Americans, at 42. The most dramatic variations occur by gender, with fistula use at just 40 percent among women, compared to 57 percent among men. Patients age 65 and older have the lowest use by age of fistulas as their primary access, at 47 percent, compared to 55 percent among those age 18–44.

Among prevalent hemodialysis patients, use of a catheter as the only mode of vascular access has remained relatively stable since the late 1990s. At 28 percent overall in 2007, use ranges by race from 19 percent among Asian patients to 29 percent among whites. Use remains highest among women, at 32 percent compared to 24 percent for

men, and is similar among age groups, at 27–29 percent for most ages.

Overall, just 35 percent of patients starting hemodialysis therapy in 2011 — 31 percent of women, and 38 percent of men — had a maturing AV fistula or were using one as their primary vascular access. This varied by race from 34 percent among blacks/African Americans to 41 percent among American Indians/Alaskan Natives.

Programs such as HP2020 and the Fistula First Initiative continue to work to increase the use of fistulas and promote early placement prior to initiation of ESRD therapy. ♦ **Tables HP2020 CKD-II**; see page 429 for analytical methods. *Prevalent hemodialysis patients; ESRD CPM data. Vascular access determined from “current access” within CPM data. Prevalent year represents year of data collection. DNC: data not collected (11.1–2). Incident hemodialysis patients age 18 & older (11.3).*

### HP2020 CKD-II.1 TARGET: 50.6%

Increase the proportion of adult hemodialysis patients who use an arteriovenous fistula as the primary mode of vascular access

	Prevalent year									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
All	27.1	27.9	29.9	31.6	33.1	36.6	39.4	44.2	46.0	49.6
American Indian or Alaskan Native only	39.0	37.7	38.2	45.3	41.0	54.3	44.3	55.3	57.7	56.6
Asian only	32.8	30.6	33.3	35.3	35.6	48.9	44.4	47.9	55.9	57.4
Native Hawaiian or other Pacific Islander only	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC
Black or African American only	22.4	22.9	25.9	26.7	28.4	29.6	35.2	38.0	40.0	42.4
White only	29.5	30.0	32.0	34.1	35.6	39.4	41.6	47.5	48.6	53.2
2 or more races	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC
Hispanic or Latino	28.5	30.4	32.1	33.5	38.8	39.5	42.6	51.6	51.9	53.0
Not Hispanic or Latino	26.9	27.7	29.8	31.4	32.2	36.2	39.1	43.0	45.0	49.0
Black or Af Am only, not Hispanic/Latino	22.3	23.2	25.8	26.8	28.3	29.6	35.2	37.8	39.7	42.3
White only, not Hispanic or Latino	30.0	30.5	32.5	34.2	34.7	39.3	41.2	46.2	47.6	53.1
Male	36.0	36.4	39.6	41.7	42.6	45.6	49.1	52.9	54.1	57.4
Female	17.0	18.2	19.4	20.4	21.9	26.4	29.4	33.8	35.5	39.9
18-44	35.6	36.1	40.8	41.0	41.7	46.8	49.8	52.2	53.2	54.8
18-24	41.2	47.5	48.6	39.6	42.7	51.9	39.0	52.7	54.7	52.2
25-44	35.1	35.1	40.1	41.1	41.6	46.4	50.5	52.2	53.1	55.0
45-64	29.2	29.1	31.2	33.8	35.5	37.2	39.6	45.1	46.9	50.7
45-54	31.0	31.5	34.5	36.4	38.3	39.4	40.8	46.0	49.1	52.7
55-64	27.7	27.0	28.6	31.8	33.1	35.4	38.6	44.4	45.3	49.3
65+	22.1	23.7	25.0	26.4	28.0	32.6	36.0	41.0	42.9	46.9
65-74	23.0	23.5	25.9	27.3	28.3	33.8	36.3	42.2	43.6	46.6
75-84	22.3	24.4	24.9	25.6	28.3	32.6	36.7	41.6	43.2	48.2
85+	12.7	20.8	19.2	23.7	24.6	25.3	31.1	32.2	38.0	43.7



**HP2020 CKD-II.2 TARGET: 26.1%**

Decrease the proportion of adult hemodialysis patients who use catheters as the only mode of vascular access

	Prevalent year									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
All	19.5	23.3	24.5	25.3	26.8	26.8	27.5	27.8	29.0	27.7
American Indian or Alaskan Native only	15.9	15.6	20.1	21.7	17.4	17.1	22.8	22.4	18.8	23.7
Asian only	12.5	15.0	16.8	17.8	21.6	15.8	19.9	23.2	20.1	19.0
Native Hawaiian or other Pacific Islander only	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC
Black or African American only	17.5	22.1	21.8	23.3	25.3	26.5	26.0	25.9	28.5	27.3
White only	21.4	24.7	26.9	27.4	28.3	28.1	29.2	29.5	30.3	28.7
2 or more races	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC	DNC
Hispanic or Latino	16.7	20.7	22.1	21.3	22.6	23.6	23.7	23.7	23.4	24.7
Not Hispanic or Latino	19.9	23.4	24.6	25.8	27.4	27.2	28.0	28.5	29.9	28.2
Black or Af Am only, not Hispanic/Latino	17.5	21.5	21.8	23.4	25.4	26.2	25.9	25.6	28.8	27.3
White only, not Hispanic or Latino	22.6	25.7	27.7	28.8	29.6	29.6	30.5	31.3	32.3	30.0
Male	17.5	20.7	20.5	21.6	23.7	23.8	23.8	24.2	25.3	24.4
Female	21.7	26.1	28.8	29.5	30.5	30.3	31.7	32.0	33.7	31.7
18-44	18.7	24.2	24.3	24.1	26.4	24.0	26.1	26.0	27.6	27.0
18-24	17.5	24.6	21.9	33.3	32.0	29.6	40.3	33.3	29.1	37.0
25-44	18.8	24.2	24.5	23.5	25.9	23.4	25.2	25.4	27.5	26.2
45-64	17.5	21.6	21.9	23.6	24.4	25.6	26.1	26.7	27.2	26.9
45-54	18.6	21.5	21.0	23.3	24.9	24.5	25.4	26.6	25.6	26.6
55-64	16.6	21.7	22.6	23.8	23.9	26.6	26.6	26.7	28.3	27.1
65+	21.4	24.3	26.7	27.2	29.0	28.9	29.1	29.3	31.1	28.6
65-74	18.1	22.1	25.5	24.9	27.4	25.9	27.4	26.9	29.0	27.1
75-84	24.1	26.0	26.1	28.5	30.1	30.3	28.9	30.5	32.0	28.3
85+	38.0	33.2	39.5	38.7	33.6	41.0	40.3	36.8	37.4	37.1





pr  
hp

1

2

3

4

5

6

7

8

9

10

11

12

**HP2020 CKD-II.3 TARGET: 34.5%**

Increase the proportion of adult hemodialysis patients who use arteriovenous fistulas or have a maturing fistula as the primary mode of vascular access at the start of renal replacement therapy

	Incident year						
	2005	2006	2007	2008	2009	2010	2011
All	30.9	31.7	31.4	30.9	32.0	33.6	34.8
American Indian or Alaskan Native only	36.3	38.8	25.8	41.4	41.0	40.9	40.6
Asian only	36.0	37.2	26.2	35.5	35.3	37.2	36.9
Native Hawaiian or other Pacific Islander only	40.0	34.9	23.6	32.6	32.1	32.4	35.8
Black or African American only	28.3	29.2	24.0	29.0	30.5	31.9	33.9
White only	31.6	32.4	28.6	31.4	32.4	34.0	35.0
2 or more races	22.6	38.1	23.8	27.8	38.3	34.9	37.3
Hispanic or Latino	30.6	31.3	20.5	29.0	30.5	32.1	32.5
Not Hispanic or Latino	30.9	31.7	28.2	31.2	32.3	33.8	35.2
Black or Af Am only, not Hispanic/Latino	28.2	29.1	24.1	29.0	30.4	31.7	33.8
White only, not Hispanic or Latino	31.9	32.7	30.4	32.1	33.0	34.7	35.8
Male	34.7	34.9	34.6	33.7	34.6	36.0	37.5
Female	26.1	27.7	27.3	27.4	28.6	30.3	31.2
18-44	28.9	29.0	27.7	27.2	28.8	30.7	31.2
18-24	25.0	23.1	20.8	21.7	22.7	23.7	25.2
25-44	29.4	29.6	28.5	27.8	29.4	31.4	31.9
45-64	32.9	33.0	32.3	32.2	33.0	34.1	35.5
45-54	32.0	32.7	32.1	31.8	32.4	33.8	35.5
55-64	33.5	33.2	32.5	32.4	33.3	34.3	35.5
65+	29.8	31.4	31.5	30.8	32.1	33.9	35.1
65-74	31.6	33.4	33.8	32.7	34.2	35.8	36.9
75-84	29.4	30.6	30.5	30.6	31.6	33.7	34.9
85+	23.5	25.0	25.1	23.8	25.3	26.5	27.8



## HP2020 CKD-I2

Increase the proportion of dialysis patients wait-listed and/or receiving a deceased donor kidney transplant within one year of end-stage renal disease start (among patients under 70 years of age)

Among 2010 ESRD patients younger than 70, 16.9 percent were wait-listed or received a deceased donor kidney transplant within one year of initiation — slightly below the HP2020 target of 18.8 percent.

The target is currently met only among Asians, individuals of two or more races, those younger than 18,

and those age 18–44. Groups furthest from the target include American Indians/Alaskan Natives and those older than 65. + **Table HP2020 CKD-I2**; see page 429 for analytical methods.

*Incident ESRD patients younger than 70. \*Values for cells with ten or fewer patients are suppressed.*

### TARGET: 18.8% OF DIALYSIS PATIENTS

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
All	14.5	14.1	14.4	14.5	15.2	15.8	16.7	16.7	16.6	17.0	16.9
American Indian or Alaskan Native only	12.4	9.1	10.1	9.5	10.2	10.9	10.1	11.2	10.7	11.2	11.4
Asian only	26.9	29.6	28.8	28.7	32.0	28.1	30.9	30.3	31.0	31.9	31.8
Native Hawaiian or other Pacific Islander only	18.7	19.5	21.9	22.2	20.1	18.0	17.4	17.4	16.4	17.7	17.7
Black or African American only	10.8	10.2	10.7	10.5	11.7	12.1	13.1	13.2	13.2	13.9	13.9
White only	16.4	15.9	16.2	16.5	16.7	17.5	18.3	18.2	17.9	18.0	17.8
2 or more races	*	*	*	*	*	16.5	18.6	13.8	22.9	22.7	23.3
Hispanic or Latino	12.2	12.8	13.5	13.8	13.8	15.0	16.6	16.5	16.6	17.0	16.6
Not Hispanic or Latino	14.9	14.4	14.6	14.6	15.4	15.8	16.7	16.7	16.5	16.9	17.0
Black or Af Am only, not Hispanic/Latino	10.9	10.2	10.7	10.5	11.6	12.0	13.0	13.2	13.2	13.8	14.0
White only, not Hispanic or Latino	17.3	16.6	16.8	16.9	17.2	18.1	18.8	18.7	18.2	18.2	18.1
Male	15.8	15.0	15.7	15.7	16.5	16.8	17.9	17.6	17.4	17.9	17.7
Female	12.9	13.1	12.8	13.1	13.7	14.4	15.3	15.5	15.5	15.7	15.8
<18	42.5	44.6	44.6	50.6	45.5	51.9	56.4	54.2	56.0	50.5	46.3
0-4	23.4	28.4	31.6	42.2	33.8	34.1	40.1	34.3	37.6	32.3	24.0
5-11	45.7	56.0	47.0	51.3	50.0	59.2	60.0	64.4	65.9	59.5	57.5
12-17	47.0	43.9	46.9	52.7	47.4	54.1	60.4	57.4	58.8	55.9	54.5
18-44	25.5	24.6	24.4	23.6	24.9	24.5	25.6	25.0	24.7	25.1	24.9
18-24	31.2	28.8	30.9	29.4	32.3	26.2	30.4	30.0	28.1	29.3	30.8
25-44	25.0	24.3	23.9	23.1	24.3	24.4	25.2	24.5	24.4	24.7	24.3
45-64	13.4	13.0	13.2	13.6	14.0	14.6	15.5	15.7	15.4	15.7	15.8
45-54	17.3	16.9	16.9	16.6	16.7	16.8	18.1	18.3	17.1	18.2	18.1
55-64	10.5	10.1	10.5	11.4	12.0	13.1	13.7	13.9	14.2	14.1	14.3
65+	4.7	5.1	5.9	6.2	7.4	8.0	9.0	9.3	9.8	10.8	11.0
65-69	4.7	5.1	5.9	6.2	7.4	8.0	9.0	9.3	9.8	10.8	11.0



## HP2020 CKD-I3

Increase the proportion of patients with treated chronic kidney failure who receive a transplant (among patients under 70 years of age)

The goal of Objective 13.1 is to have 19.7 percent of incident ESRD patients younger than 70 transplanted within three years of initiation; for patients beginning ESRD therapy in 2008, the rate was 15.2 percent, one percentage point lower than the previous year, and continuing to move further from the target. Rates are lowest among blacks/African Americans and American Indians/Alaskan Natives, at 7–9 percent. The percentage transplanted falls with age, from 72 in

pediatric patients to 8.1 among those age 65 and older.

The percentage of patients receiving a preemptive transplant at the start of ESRD (Objective 13.2) has risen only slightly over the past decade, from 2.9 in 2001 to 3.3 in 2011. Preemptive transplants are most common in pediatric patients, reaching 24 percent among those age 5–11. **† Tables HP2020 CKD-13; see page 429 for analytical methods. Incident ESRD patients younger than 70. \*Values for cells with ten or fewer patients are suppressed.**

### HP2020 CKD-I3.I TARGET: 19.7%

Increase the proportion of patients receiving a kidney transplant within three years of end-stage renal disease

	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
All	20.0	19.5	19.1	18.4	18.4	17.8	17.9	17.3	16.7	16.2	15.2
American Indian or Alaskan Native only	11.6	9.9	15.8	8.6	11.6	8.8	9.3	8.8	10.1	10.0	7.1
Asian only	19.7	18.8	19.7	19.5	21.7	22.4	20.5	18.3	18.7	17.3	17.8
Native Hawaiian or other Pacific Islander only	14.0	15.6	9.0	14.7	14.4	13.5	13.9	10.3	10.9	12.2	12.5
Black or African American only	9.9	9.7	9.9	8.9	9.7	9.3	10.1	9.7	9.1	9.0	8.6
White only	27.0	26.3	25.3	24.4	23.8	23.3	22.7	22.1	21.3	20.4	19.0
2 or more races	*	*	*	*	*	*	*	17.2	16.1	14.2	17.6
Hispanic or Latino	17.0	15.2	15.3	14.9	14.6	14.6	13.9	14.0	13.7	12.9	11.9
Not Hispanic or Latino	20.5	20.2	19.9	19.0	19.1	18.4	18.5	17.7	17.2	16.8	15.8
Black or Af Am only, not Hispanic/Latino	9.9	9.7	10.0	8.9	9.7	9.3	10.0	9.5	8.9	8.9	8.5
White only, not Hispanic or Latino	29.0	28.9	27.7	26.9	26.5	25.7	25.1	24.4	23.7	23.0	21.6
Male	22.0	21.2	20.6	19.8	20.0	19.5	19.3	18.7	18.1	17.0	15.8
Female	17.6	17.4	17.3	16.6	16.3	15.8	16.1	15.5	14.9	15.0	14.4
<18	75.1	76.1	73.4	73.0	74.5	76.2	74.4	74.4	74.8	75.1	71.9
0-4	76.3	81.0	76.8	75.8	79.7	78.1	78.2	73.3	75.3	73.3	64.9
5-11	82.0	79.0	76.5	82.2	79.2	82.0	82.6	79.5	78.5	85.0	83.8
12-17	71.3	73.4	70.8	67.7	70.8	73.1	69.9	72.7	73.7	72.4	70.0
18-44	33.8	32.6	31.5	30.2	29.8	28.4	28.5	26.7	25.7	24.4	22.7
18-24	44.6	42.8	44.3	42.5	39.6	41.4	39.9	36.9	35.0	33.1	30.4
25-44	32.6	31.5	30.1	28.8	28.7	26.8	27.2	25.5	24.6	23.4	21.8
45-64	16.2	15.7	15.9	15.3	15.1	14.9	15.0	14.8	14.3	13.8	13.1
45-54	20.9	20.2	20.3	19.5	18.5	18.2	18.3	17.2	16.7	16.6	15.3
55-64	12.4	12.0	12.4	11.9	12.5	12.4	12.5	13.0	12.4	11.9	11.5
65+	5.3	6.0	6.2	6.4	7.4	7.7	8.0	7.7	8.3	8.1	8.1
65-69	5.3	6.0	6.2	6.4	7.4	7.7	8.0	7.7	8.3	8.1	8.1



**HP2020 CKD-I3.2**

Increase the proportion of patients who receive a preemptive transplant at the start of ESRD

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	2.9	3.0	2.9	3.1	3.3	3.4	3.5	3.4	3.2	3.3	3.3
American Indian or Alaskan Native only	*	*	1.5	*	*	1.4	*	*	1.7	*	3.1
Asian only	2.4	3.0	2.8	2.6	2.7	2.8	2.9	3.2	3.0	3.7	7.1
Native Hawaiian or other Pacific Islander only	*	*	*	*	*	*	2.1	3.0	2.3	*	*
Black or African American only	0.7	0.8	0.8	0.8	0.9	1.0	1.0	1.0	1.0	1.1	1.2
White only	4.4	4.5	4.3	4.6	4.7	4.9	4.9	4.7	4.4	4.5	4.2
2 or more races	*	*	*	*	1.6	*	*	*	*	*	*
Hispanic or Latino	1.3	1.4	1.3	1.4	1.3	1.8	1.7	1.8	1.8	1.8	1.9
Not Hispanic or Latino	3.2	3.3	3.1	3.2	3.4	3.5	3.7	3.6	3.3	3.4	3.5
Black or Af Am only, not Hispanic/Latino	0.7	0.8	0.8	0.7	0.8	0.9	1.0	1.0	1.0	1.1	1.0
White only, not Hispanic or Latino	5.1	5.3	4.9	5.1	5.4	5.6	5.8	5.6	5.1	5.2	5.0
Male	3.0	3.1	2.9	3.1	3.3	3.5	3.6	3.3	3.2	3.2	3.3
Female	2.8	3.0	2.8	3.1	3.3	3.3	3.3	3.5	3.2	3.4	3.4
<18	18.2	17.0	15.2	15.0	17.9	17.5	16.8	16.0	18.8	16.6	18.9
0-4	16.3	10.7	14.1	15.0	14.4	11.8	15.5	8.5	10.4	10.2	12.0
5-11	19.1	24.7	22.3	17.2	22.2	23.8	25.1	25.9	27.0	26.1	24.2
12-17	18.5	15.0	12.5	14.1	17.4	17.2	14.2	15.0	19.6	16.1	20.6
18-44	5.2	5.3	4.6	5.1	4.7	5.2	5.0	4.9	4.8	4.7	5.1
18-24	7.3	6.9	7.4	7.4	6.6	8.1	6.8	6.3	6.6	7.3	7.4
25-44	5.0	5.1	4.3	4.9	4.5	4.9	4.8	4.7	4.6	4.4	4.8
45-64	2.4	2.5	2.5	2.7	2.9	3.0	3.2	3.1	2.8	3.0	2.9
45-54	3.3	3.5	3.3	3.5	3.7	3.8	4.0	3.8	3.5	3.8	3.5
55-64	1.7	1.8	1.9	2.2	2.4	2.5	2.7	2.6	2.4	2.5	2.5
65+	0.7	0.8	1.0	1.1	1.4	1.6	1.5	1.7	1.6	1.9	2.0
65-69	0.7	0.8	1.0	1.1	1.4	1.6	1.5	1.7	1.6	1.9	2.0



## HP2020 CKD-I4

Reduce deaths in persons with end-stage renal disease

Since 2001, the overall death rate among prevalent patients on dialysis has fallen 20 percent, from 235 deaths per 1,000 patient years to 188 in 2011 — for the first time meeting the HP2020 target of 190.8. By race, the rate ranges from 138 among Asians to 224 among whites; by ethnicity, it is 141 among Hispanics and Latinos and 198 among those not in either group.

The rate of mortality among dialysis patients in the first three months after initiation has fallen from its peak of 389 in 2003, but, at 335 in 2011, remains a distance from the HP2020 target of 319.9 deaths per 1,000 patient years at risk. The highest rate by race occurs among whites, at 396 compared to 147 among American Indians/Alaskan Natives, 177 among Asians, and 230 among blacks/African Americans.

The HP2020 goal of 81.3 cardiovascular deaths per 1,000 patient years was met again in 2011, with a rate of 76.6. The rate has fallen 35 percent overall since 2001, and 45 percent for

American Indians/Alaskan Natives. By race, the rate is highest among whites, at 90 compared to 57–63 among blacks/African Americans, American Indians/Alaskan Natives, and Asians.

For patients with a functioning transplant, the overall rate of mortality remained stable in 2011, at 31.9 deaths per 1,000 patient years — slightly above the HP2020 goal of 29.4. By race, mortality ranges from 16.8 among Native Hawaiians/other Pacific Islanders to 47.7 among American Indians/Alaskan Natives.

The rate of cardiovascular mortality among transplant patients has fallen 43 percent since 2001, and in 2011 reached the HP2020 target of 4.5.

♦ **Tables HP2020 CKD-I4;** see page 429 for analytical methods. *Period prevalent dialysis patients; unadjusted (14.1, 14.3). Incident dialysis patients; unadjusted (14.2). Period prevalent transplant patients; unadjusted (14.4–5).*

\*Values for cells with ten or fewer patients are suppressed.

### HP2020 CKD-I4.I TARGET: 190.8 DEATHS PER 1,000 PATIENT YEARS

Reduce the total death rate for persons on dialysis

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	235.0	232.9	231.7	227.5	223.6	219.3	211.0	203.8	198.6	191.8	187.9
American Indian or Alaskan Native only	206.5	194.7	190.1	183.3	181.3	171.5	165.3	168.9	170.5	149.6	145.5
Asian only	173.7	162.5	175.0	167.0	170.0	160.2	155.4	143.5	144.4	136.0	138.1
Native Hawaiian or other Pacific Islander only	162.1	178.2	169.4	167.3	154.9	164.6	162.4	149.1	156.3	153.6	142.8
Black or African American only	186.6	182.6	182.8	182.2	178.9	173.3	166.6	160.4	155.9	148.7	143.8
White only	280.2	279.3	276.0	268.8	264.8	260.2	249.4	240.5	233.6	227.4	224.0
2 or more races					388.6	292.4	221.6	232.1	238.3	251.4	240.0
Hispanic or Latino	186.8	185.1	184.3	178.1	173.9	166.1	155.7	150.3	149.0	141.5	140.8
Not Hispanic or Latino	242.4	240.4	239.4	235.8	232.2	228.7	221.1	213.9	208.2	201.8	197.5
Black or Af Am only, not Hispanic/Latino	186.8	182.7	182.8	182.1	178.8	173.3	166.8	160.4	156.2	148.6	143.5
White only, not Hispanic or Latino	302.5	302.4	300.3	294.0	290.9	288.5	279.2	271.8	264.4	259.7	257.3
Male	228.6	226.1	226.8	223.6	219.5	215.4	208.1	201.7	198.1	190.5	187.2
Female	242.2	240.6	237.3	232.0	228.3	223.9	214.5	206.4	199.2	193.4	188.7
<18	47.3	41.9	53.6	43.0	38.9	41.3	42.1	33.3	35.0	46.9	45.9
0-4	156.6	118.0	113.4	93.7	83.7	80.4	93.9	90.4	79.5	100.1	110.5
5-11	48.1	*	75.1	51.6	35.9	38.9	36.7	36.6	43.6	51.2	41.7
12-17	20.6	33.1	32.8	28.8	29.6	32.4	30.4	15.8	17.6	23.6	14.0
18-44	90.1	92.3	89.9	86.6	84.4	81.8	77.8	73.5	71.8	65.3	62.9
18-24	49.8	47.3	52.7	53.5	50.7	49.7	48.3	41.9	40.3	36.9	37.6
25-44	93.5	96.1	93.1	89.4	87.2	84.5	80.3	76.2	74.5	67.6	65.0
45-64	177.5	172.9	174.4	170.8	164.0	162.9	154.8	148.4	144.9	139.2	136.0
45-54	147.8	142.1	141.4	139.6	135.7	134.3	128.4	120.3	117.3	110.5	108.9
55-64	202.5	198.6	201.4	195.7	185.8	184.5	174.5	169.1	164.8	159.3	154.6
65+	352.1	348.4	343.0	337.7	335.8	327.5	317.3	308.2	299.3	290.5	285.0
65-74	290.9	286.4	281.4	275.3	271.2	260.1	249.0	244.1	239.1	230.1	224.5
75-84	406.9	398.8	390.1	385.1	382.4	375.5	363.5	351.1	337.4	328.8	322.6
85+	572.1	574.9	556.9	537.4	539.8	525.4	521.2	497.6	478.9	466.7	463.6



**HP2020 CKD-I4.2 TARGET: 319.9 DEATHS PER 1,000 PATIENT YEARS AT RISK**

Reduce the death rate in dialysis patients within the first three months of initiation of renal replacement therapy

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	384.2	383.4	389.4	384.6	379.7	373.4	367.3	363.5	354.8	353.9	335.4
American Indian or Alaskan Native only	185.0	145.7	203.0	215.2	204.6	157.5	171.2	233.1	154.9	143.5	146.9
Asian only	233.5	229.1	229.8	229.7	258.1	215.5	237.4	198.9	211.5	209.7	177.1
Native Hawaiian or other Pacific Islander only	209.5	180.9	185.1	185.1	171.6	223.8	184.3	161.2	205.3	159.6	172.4
Black or African American only	273.6	265.4	278.5	274.3	272.9	264.7	254.1	251.8	246.8	243.3	229.9
White only	447.8	451.7	455.1	446.6	435.6	430.6	427.0	423.2	413.4	415.6	396.2
2 or more races					455.3	356.3	329.8	421.3	271.8	376.1	398.1
Hispanic or Latino	278.3	250.9	270.4	255.9	260.2	233.6	239.0	227.0	217.1	222.0	212.8
Not Hispanic or Latino	399.2	403.2	407.8	404.7	398.3	395.9	388.5	386.7	378.2	377.3	357.8
Black or Af Am only, not Hispanic/Latino	273.8	265.0	278.4	274.7	271.9	264.8	254.8	251.0	246.3	242.4	230.3
White only, not Hispanic or Latino	481.7	493.0	494.6	489.0	477.5	480.7	475.9	477.9	468.0	471.9	452.2
Male	384.5	377.4	387.9	384.7	375.9	369.4	368.1	365.0	358.8	350.7	334.1
Female	383.8	390.6	391.2	384.5	384.4	378.5	366.3	361.6	349.5	358.1	337.0
<18	*	*	56.4	83.0	78.1	78.2	*	60.7	62.9	63.8	72.6
0-4	*	*	*	*	273.7	*	*	*	*	170.9	178.9
5-11	*	*	*	*	*	*	*	*	*	*	*
12-17	*	*	*	*	*	*	*	*	*	*	*
18-44	103.0	105.7	105.4	106.1	105.6	100.4	96.6	100.7	104.4	92.9	93.0
18-24	73.0	59.5	69.0	79.7	55.6	85.7	62.2	57.0	50.0	61.6	63.0
25-44	106.1	110.5	109.3	108.9	111.1	101.9	100.4	105.4	110.1	96.1	96.3
45-64	220.5	212.6	221.1	214.4	217.9	209.6	202.4	209.3	208.2	205.8	195.0
45-54	164.1	169.8	170.7	169.7	179.8	158.5	160.3	172.4	162.9	157.3	150.9
55-64	262.5	243.9	257.3	246.1	244.2	245.3	230.7	233.7	237.6	236.1	222.6
65+	583.7	584.0	593.3	590.1	580.0	577.1	572.8	558.4	540.7	540.7	513.9
65-74	433.8	429.0	424.5	425.4	418.8	408.3	408.4	408.2	391.8	391.7	368.2
75-84	678.6	679.1	683.4	681.0	660.3	663.8	654.1	620.7	615.1	613.1	590.3
85+	1,043.6	995.6	1,068.0	1,019.6	997.8	1,001.6	977.5	962.4	898.3	918.3	868.6



pr  
hp

1

2

3

4

5

6

7

8

9

10

11

12

2II

**HP2020 CKD-I4.3 TARGET: 81.3 DEATHS PER 1,000 PATIENT YEARS AT RISK**  
Reduce the cardiovascular death rate for persons on dialysis

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	118.6	115.2	112.9	107.8	101.1	95.4	90.2	85.4	82.6	79.9	76.6
American Indian or Alaskan Native only	104.0	91.4	88.8	83.5	78.1	72.4	69.2	60.6	67.7	61.5	56.7
Asian only	97.5	88.7	96.7	85.9	88.3	72.4	70.9	67.9	69.1	62.5	63.2
Native Hawaiian or other Pacific Islander only	100.2	108.5	102.5	90.6	77.0	91.0	82.2	73.8	84.2	82.4	71.9
Black or African American only	90.6	89.0	86.9	85.2	81.2	77.6	72.4	69.6	67.0	63.5	59.9
White only	143.2	139.1	135.4	128.0	119.2	111.4	105.2	98.5	95.0	93.1	89.9
2 or more races					*	104.2	97.4	97.7	95.1	104.9	114.5
Hispanic or Latino	97.6	93.4	90.2	86.0	81.7	75.4	70.1	67.1	67.5	64.5	63.0
Not Hispanic or Latino	121.8	118.7	116.5	111.5	104.5	99.0	93.8	88.8	85.6	83.0	79.4
Black or Af Am only, not Hispanic/Latino	90.6	88.8	87.0	85.1	81.1	77.5	72.5	69.5	67.1	63.5	59.8
White only, not Hispanic or Latino	154.1	150.1	147.3	139.5	129.7	122.1	116.5	109.5	105.0	103.7	100.5
Male	117.8	114.5	113.0	108.6	101.8	96.4	91.1	87.1	84.9	81.7	78.5
Female	119.5	116.0	112.7	107.0	100.4	94.3	89.0	83.3	79.8	77.7	74.2
<18	17.5	13.7	11.0	13.7	15.6	15.4	10.2	9.0	14.0	11.6	11.8
0-4	60.6	*	*	*	*	*	*	*	*	*	27.1
5-11	*	*	*	*	*	*	*	*	*	*	*
12-17	*	*	*	*	15.3	14.5	*	*	*	*	*
18-44	40.5	41.5	39.8	38.8	37.6	35.6	32.9	31.2	31.0	29.1	26.8
18-24	20.6	19.4	24.2	24.5	23.7	19.0	18.8	15.5	17.9	18.2	18.1
25-44	42.1	43.3	41.1	40.0	38.8	37.0	34.1	32.5	32.2	30.0	27.5
45-64	89.7	86.7	84.9	81.5	75.8	73.5	68.7	65.5	63.8	61.1	59.2
45-54	73.1	69.6	67.1	64.3	61.2	60.1	57.1	53.2	52.2	47.7	48.3
55-64	103.7	100.9	99.5	95.2	87.1	83.7	77.3	74.5	72.2	70.6	66.7
65+	179.7	173.2	168.9	160.6	150.6	140.0	133.3	125.7	120.6	117.3	112.0
65-74	150.7	143.7	139.7	133.4	123.8	114.9	108.1	104.4	101.2	96.8	93.1
75-84	206.1	196.8	191.5	181.1	171.1	157.2	151.3	139.3	131.7	130.6	123.8
85+	282.5	282.6	268.4	248.2	229.8	217.1	204.3	191.5	183.2	175.5	167.7

L'AMERIQUE  
divise  
PAR GRANDS ETATS  
Par le Dr. J. B. L. G. G. G. G. G.  
A PARIS  
chez les Libraires, les Pharmaciens, les  
Lettres, les Sciences, les Arts, les  
Lettres, les Sciences, les Arts, les



**HP2020 CKD-I4.4 TARGET: 29.4 DEATHS PER 1,000 PATIENT YEARS AT RISK**  
 Reduce the total death rate for persons with a functioning kidney transplant

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	34.7	33.0	33.7	32.2	32.8	32.5	31.8	30.8	32.0	31.7	31.9
American Indian or Alaskan Native only	42.8	38.4	39.1	34.3	39.5	44.9	36.1	38.1	58.8	48.0	47.7
Asian only	18.6	23.4	18.9	20.2	22.4	19.9	25.2	20.3	17.5	16.8	22.1
Native Hawaiian or other Pacific Islander only	30.8	31.9	30.5	31.6	33.5	20.0	13.9	18.3	26.3	21.2	16.8
Black or African American only	38.4	36.6	37.5	34.2	34.7	34.8	31.4	30.8	30.8	31.2	31.2
White only	34.3	33.0	33.5	32.3	32.8	32.7	32.7	31.1	33.0	32.8	32.9
2 or more races					*	*	*	*	*	*	*
Hispanic or Latino	27.4	23.5	23.0	23.0	24.7	26.9	23.2	24.4	23.8	23.9	23.3
Not Hispanic or Latino	35.5	34.1	35.0	33.4	33.9	33.2	33.0	31.7	33.2	33.0	33.3
Black or Af Am only, not Hispanic/Latino	38.6	36.9	37.3	34.3	34.9	35.1	31.3	31.0	30.7	31.5	31.4
White only, not Hispanic or Latino	35.1	34.0	34.9	33.6	33.8	33.4	34.3	32.3	34.7	34.4	34.8
Male	36.9	34.8	35.1	34.3	35.3	34.5	33.8	32.4	33.5	33.8	34.0
Female	31.5	30.3	31.6	29.2	29.3	29.6	28.9	28.4	29.8	28.7	28.8
<18	5.0	8.3	6.7	3.8	7.4	3.6	*	3.2	3.8	6.1	3.0
0-4	*	*	*	*	*	*	*	*	*	*	*
5-11	*	*	*	*	*	*	*	*	*	*	*
12-17	5.4	7.2	6.0	*	8.7	*	*	*	*	6.1	*
18-44	16.2	14.5	13.0	12.6	12.3	11.8	11.4	10.4	10.3	9.5	9.0
18-24	9.3	5.0	6.1	7.3	7.8	8.4	7.0	8.0	7.2	6.6	5.1
25-44	16.9	15.5	13.7	13.1	12.8	12.2	11.9	10.6	10.7	9.9	9.5
45-64	39.9	36.7	37.2	34.1	34.2	33.3	30.8	29.6	29.4	28.4	28.6
45-54	31.1	29.0	28.1	25.1	26.2	25.7	22.8	22.7	22.9	19.6	19.3
55-64	52.5	47.3	49.0	45.1	43.6	41.7	39.3	36.7	35.7	36.6	37.0
65+	93.0	89.0	90.6	86.3	84.3	80.8	80.7	74.4	77.1	75.5	73.2
65-74	86.7	83.4	82.1	78.5	77.1	71.7	71.8	64.3	67.0	66.0	62.6
75-84	141.7	129.8	149.7	133.8	124.1	129.6	122.6	120.8	121.9	113.4	113.8
85+	*	*	*	221.9	237.5	140.8	239.4	158.8	136.3	174.3	165.6





pr  
hp

1

2

3

4

5

6

7

8

9

10

11

12

213

**HP2020 CKD-I4.5 TARGET: 4.5 DEATHS PER 1,000 PATIENT YEARS AT RISK**  
 Reduce the cardiovascular death rate in persons with a functioning transplant

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
All	7.8	7.0	7.2	7.2	6.7	6.5	6.3	5.2	5.4	5.5	4.5
American Indian or Alaskan Native only	*	*	*	*	*	10.5	7.4	*	10.0	*	7.9
Asian only	4.7	7.1	3.4	*	3.5	4.6	5.0	3.1	1.9	2.9	2.7
Native Hawaiian or other Pacific Islander only	*	*	*	*	*	*	*	*	*	*	*
Black or African American only	9.8	8.6	9.2	9.1	7.6	7.6	6.9	5.8	6.2	6.2	5.1
White only	8.1	7.1	7.4	7.4	6.8	6.5	6.5	5.4	5.5	5.7	4.6
2 or more races					*	*	*	*	*	*	*
Hispanic or Latino	6.9	6.6	5.9	5.9	5.7	6.1	4.6	4.7	4.1	4.0	3.8
Not Hispanic or Latino	7.9	7.0	7.3	7.4	6.8	6.5	6.6	5.3	5.6	5.7	4.6
Black or Af Am only, not Hispanic/Latino	10.0	8.7	9.1	8.9	7.8	7.7	6.9	5.9	6.3	6.1	5.1
White only, not Hispanic or Latino	8.2	7.1	7.6	7.6	6.9	6.5	6.8	5.5	5.8	6.1	4.7
Male	8.7	7.5	7.6	8.0	7.3	7.0	7.1	5.8	5.4	5.9	5.0
Female	6.5	6.1	6.6	6.1	5.8	5.7	5.2	4.3	5.3	4.8	3.7
<18	*	*	*	*	*	*	*	*	*	*	*
0-4	*	*	*	*	*	*	*	*	*	*	*
5-11	*	*	*	*	*	*	*	*	*	*	*
12-17	*	*	*	*	*	*	*	*	*	*	*
18-44	3.6	3.2	2.9	3.0	2.7	2.5	2.5	2.1	1.8	1.7	1.3
18-24	*	*	*	*	*	*	*	*	*	*	*
25-44	3.8	3.4	3.1	3.2	2.9	2.6	2.5	2.3	1.9	1.8	1.4
45-64	9.3	8.0	8.3	8.1	7.0	7.1	6.5	5.4	5.0	5.3	4.5
45-54	8.3	5.7	6.6	6.8	5.4	5.4	5.5	4.1	4.2	3.5	3.0
55-64	10.8	11.0	10.5	9.7	8.9	9.0	7.7	6.7	5.9	7.0	5.8
65+	19.4	17.5	17.2	17.4	16.6	13.9	14.2	10.7	12.5	11.8	9.0
65-74	18.8	16.7	15.2	16.5	15.9	12.1	12.6	9.8	11.1	10.8	8.4
75-84	24.2	23.7	31.9	23.3	19.6	24.4	21.9	15.3	19.2	15.7	11.3
85+	*	*	*	*	*	*	*	*	*	*	*

LA MERIQUE  
 dirigee  
 PAR GRANDS ETATS  
 Par le Dr. JANTIER  
 A PARIS



## *recommended care*

PATIENTS WITH DIAGNOSED DIABETES WHO OBTAIN AN ANNUAL URINE ALBUMIN MEASUREMENT, 2011 (DIABETES-12)

TARGET: 37 PERCENT

all: 41%; American Indian/Alaskan Native: 25%; Asian: 44%; black/African American: 39%; white: 41%; Hispanic or Latino: 43%

## *acei/arb treatment*

PATIENTS WITH DIABETES & CKD WHO RECEIVE TREATMENT WITH AN ACEI OR ARB, 2011 (CKD-5)

TARGET: 60 PERCENT

all: 72%; American Indian/Alaskan Native: 75%; Asian: 80%; black/African American: 75%; white: 70%; Hispanic or Latino: 79%

## *incidence of end-stage renal disease*

RATE PER MILLION POPULATION OF NEW CASES OF END-STAGE RENAL DISEASE, 2011 (CKD-8)

TARGET: 318.5 NEW CASES PER MILLION POPULATION

all: 357; American Indian/Alaskan Native: 457; Asian: 347; Native Hawaiian/Pacific Islander: 2,368;  
black/African American: 971; white: 286; Hispanic or Latino: 537

## *kidney failure due to diabetes*

RATE PER MILLION POPULATION OF NEW CASES OF END-STAGE RENAL DISEASE DUE TO DIABETES, 2011 (CKD-9.1)

TARGET: 139.2 PER MILLION POPULATION

all: 156; American Indian/Alaskan Native: 320; Asian: 173; Native Hawaiian/Pacific Islander: 1,439;  
black/African American: 424; white: 127; Hispanic or Latino: 329

## *nephrologist care*

PATIENTS RECEIVING AT LEAST 12 MONTHS OF NEPHROLOGIST CARE PRIOR TO INITIATION, 2011 (CKD-10)

TARGET: 29.8 PERCENT

all: 31%; American Indian/Alaskan Native: 28%; Asian: 31%; Native Hawaiian/Pacific Islander: 27%;  
black/African American: 27%; white: 33%; Hispanic or Latino: 24%; not Hispanic or Latino: 32%

## *vascular access*

ADULT INCIDENT HD PATIENTS WITH A MATURING AV FISTULA OR USING ONE AS THEIR PRIMARY VASCULAR ACCESS, 2011 (CKD-11.3)

TARGET: 34.5 PERCENT

all: 35%; American Indian/Alaskan Native: 41%; Asian: 37%; Native Hawaiian/Pacific Islander: 36%;  
black/African American: 34%; white: 35%; Hispanic or Latino: 33%; not Hispanic or Latino: 35%

## *transplantation*

PATIENTS WAIT-LISTED OR RECEIVING A DECEASED DONOR KIDNEY WITHIN ONE YEAR OF ESRD INITIATION IN 2010 (CKD-12)

TARGET: 18.8 PERCENT

all: 17%; American Indian/Alaskan Native: 11%; Asian: 32%; Native Hawaiian/Pacific Islander: 18%;  
black/African American: 14%; white: 18%; Hispanic or Latino: 17%; not Hispanic or Latino: 17%

## *mortality*

OVERALL MORTALITY (DEATHS PER 1,000 PATIENT YEARS AT RISK) AMONG PATIENTS ON DIALYSIS, 2011 (CKD-14.1)

TARGET: 190.8 DEATHS PER 1,000 PATIENT YEARS

all: 188; American Indian/Alaskan Native: 146; Asian: 138; Native Hawaiian/Pacific Islander: 143;  
black/African American: 144; white: 224; Hispanic or Latino: 141; not Hispanic or Latino: 198

